KDNY'un PB Oranı emsallerine kıyasla nasıldır?

KDNY Price-To-Book Oranı ( 8.1 x) açısından benzer ortalamaya ( 4.8 x) kıyasla pahalıdır.

KDNY'nin PB Oranı, US Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

KDNY Price-To-Book Oranı ( 8.1 x) baz alındığında, US Biotechs sektör ortalamasına ( 1.8 x) kıyasla pahalıdır.

KDNY'nin PB Oranı, Adil PB Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PB Oranıdır.

Değerleme analizi için KDNY 'in Price-To-Book Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında KDNY 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

KDNY 'un değerleme analizi için adil değerinin hesaplanmasında yeterli veri bulunmamaktadır.

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Hedef fiyat, mevcut hisse fiyatının altındadır.

Chinook Therapeutics (Nasdaq:KDNY) - Hisse Senedi Fiyatı, Haberler ve Analizler

KDNY Stoklara Genel Bakış

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.

Şirket hakkında

KDNY temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 63.8% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Chinook Therapeutics, Inc. Rakipler

Janux Therapeutics

NasdaqGM:JANX

US$2.8b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.6b

Apellis Pharmaceuticals

NasdaqGS:APLS

US$3.4b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Chinook Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$40.39
52 Haftanın En Yüksek Seviyesi	US$40.51
52 Haftanın En Düşük Seviyesi	US$18.34
Beta	0.67
11 Aylık Değişim	2.98%
3 Aylık Değişim	72.68%
1 Yıllık Değişim	95.69%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	173.46%

Son Haberler & Güncellemeler

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Hissedar Getirileri

	KDNY	US Biotechs	US Pazar
7D	0.3%	-1.4%	-1.9%
1Y	95.7%	20.2%	30.4%

Getiri vs. Endüstri: KDNY geçen yıl % 20.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: KDNY geçen yıl % 30.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is KDNY's price volatile compared to industry and market?
KDNY volatility
KDNY Average Weekly Movement	17.1%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: KDNY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: KDNY 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 10% dan 17% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. Temel Bilgiler Özeti

Chinook Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
KDNY temel i̇stati̇sti̇kler
Piyasa değeri	US$2.90b
Kazançlar(TTM)	-US$245.65m
Gelir(TTM)	US$5.85m

495.8x

P/S Oranı

-11.8x

F/K Oranı

KDNY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
KDNY gelir tablosu (TTM)
Gelir	US$5.85m
Gelir Maliyeti	US$193.72m
Brüt Kâr	-US$187.87m
Diğer Giderler	US$57.79m
Kazançlar	-US$245.65m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.42
Brüt Marj	-3,211.95%
Net Kâr Marjı	-4,199.93%
Borç/Özkaynak Oranı	0%

KDNY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

KDNY Stoklara Genel Bakış

Ödüller

Risk Analizi

Chinook Therapeutics, Inc. Rakipler

NasdaqGM:JANX

US$2.8b

NasdaqCM:CPRX

US$2.6b

NasdaqGS:APLS

US$3.4b

NasdaqGS:TPTX

US$3.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Chinook Therapeutics, Inc. Temel Bilgiler Özeti

495.8x